周五盘中，三生制药（01530.HK）股价大涨5.83%，引发市场关注。这一显著涨幅主要源于公司近期发布的2024年度业绩报告，展现出强劲的增长势头。
根据三生制药公布的2024年财报，公司取得了令人瞩目的业绩。营收达91.1亿元人民币，同比增长16.5%；归母净利润20.9亿元，同比增长34.9%。公司核心产品表现突出，特比奥收入50.6亿元，同比增长20.4%，市场占有率高达67%；蔓迪销售额为13.37亿元，同比增长18.9%。这些数据显示，三生制药在市场竞争中保持了强劲的增长动力。
除了财务业绩亮眼外，三生制药在研发方面也取得了重大进展。2024年，公司有3款新药获批上市，4款新药进入上市申报阶段。特别值得关注的是，公司的靶向PD-1/VEGF双特异性抗体707在非小细胞肺癌等适应症的二期临床中显示出优于竞品的疗效潜力。此外，公司还达成了4项商业开发合作，包括引进司美格鲁肽注射液减重适应症等。这些积极因素无疑增强了投资者对公司未来发展前景的信心，推动了股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.